Adma Biologics (ADMA) Operating Expenses (2011 - 2025)

Adma Biologics has reported Operating Expenses for 13 years, with the latest figure at $26.1 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses rose 4.22% year-over-year to $26.1 million; the trailing twelve-month figure through Dec 2025 stood at $101.3 million (up 25.76% YoY), and the FY2025 full-year result was $101.3 million, up 25.76% from the prior year.
• Operating Expenses for Q4 2025 stood at $26.1 million, up from $24.6 million in the prior quarter.
• The five-year high for Operating Expenses was $26.2 million in Q1 2025, with the low at $13.4 million in Q1 2021.
• Historically, Operating Expenses has averaged $19.2 million across 5 years, with a median of $17.8 million in 2023.
• The largest YoY upside for Operating Expenses was 155.46% in 2021 against a maximum downside of 50.16% in 2021.
• Adma Biologics' Operating Expenses stood at $16.7 million in 2021, then climbed by 21.15% to $20.2 million in 2022, then slipped by 16.72% to $16.9 million in 2023, then jumped by 48.4% to $25.0 million in 2024, then grew by 4.22% to $26.1 million in 2025.
• The last three Operating Expenses figures came in at $26.1 million (Q4 2025), $24.6 million (Q3 2025), and $24.4 million (Q2 2025), per Business Quant data.